One barrier to enrolling minorities in research involves resources. For some studies, such as pediatric oncology clinical trials, there might not be enough resources to enroll one or two patients at a single site.

Many oncologists may cite fear of giving up hope as a primary reason they defer conversations about end-of-life or advance care planning until late in the course of a patient’s disease.

Recently, melatonin and its potential benefits in cancer and chemotherapy have been discussed in varying publications. However, it is unclear how many individuals may be using it to promote sleep or for other health reasons such as an adjunctive therapy in cancer treatment.